JOHANNESBURG (Reuters) – South Africa’s Aspen Pharmacare is in talks with Johnson & Johnson to produce the finished drug ingredient for manufacturing COVID-19 vaccine, according to a presentation uploaded on the company’s website on Thursday.
“The technical transfer agreement is under way with Johnson & Johnson to manufacture the FDF of their candidate COVID-19
vaccine Ad26.COV2-S,” the presentation said.
(Reporting by Promit Mukherjee; Editing by David Goodman)
